Having trouble accessing articles? Reset your cache.

Alexion deal lends late-stage support to Stealth

Alexion continued its run of deals by obtaining an option to a Phase III candidate from Stealth, which would get a boost in building its commercial infrastructure ahead of a regulatory submission next year and be able to devote more resources to its earlier stage programs.

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) will receive an option to license exclusive

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE